{"id":9108,"date":"2021-04-13T09:46:49","date_gmt":"2021-04-13T16:46:49","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=9108"},"modified":"2021-04-14T09:47:30","modified_gmt":"2021-04-14T16:47:30","slug":"inhaled-budesonide-for-covid-19-in-people-at-higher-risk-of-adverse-outcomes-in-the-community-interim-analyses-from-the-principle-trial","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/04\/13\/inhaled-budesonide-for-covid-19-in-people-at-higher-risk-of-adverse-outcomes-in-the-community-interim-analyses-from-the-principle-trial\/","title":{"rendered":"Inhaled Budesonide for COVID-19 in People at Higher Risk of Adverse Outcomes in the Community Interim Analyses from the PRINCIPLE Trial"},"content":{"rendered":"<ul>\n<li style=\"font-weight: 400\"><i><span style=\"font-weight: 400\">[Pre-print, not peer-reviewed]<\/span><\/i><span style=\"font-weight: 400\"> The inhaled corticosteroid budesonide reduced time to recovery among older ambulatory SARS-CoV-2-infected adults by 3 days, according to an interim analysis of a randomized, open-label trial (PRINCIPLE Trial). In participants either 65 years and older without co-morbidities or less than 50 years with co-morbidities given 14 days of 800 mcg of budesonide twice daily, there were 59 out of 692 (8.5%) COVID-19 related hospitalizations\/deaths in the budesonide group vs 100 out of 968 (10.3%) in the usual care group, a result which was not statistically significant (estimated percentage benefit, 2.1% [95% BCI \u22120.7% \u2013 4.8%], probability of superiority 0.928). The authors note that not all participants had completed 28-day follow-up and that the study will have higher power to detect prevention of hospitalization once all data are analyzed.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Yu et al.\u00a0(Apr 12, 2021). Inhaled Budesonide for COVID-19 in People at Higher Risk of Adverse Outcomes in the Community Interim Analyses from the PRINCIPLE Trial. Pre-print downloaded Apr 13 from <\/span><\/i><a href=\"https:\/\/doi.org\/10.1101\/2021.04.10.21254672\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1101\/2021.04.10.21254672<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>[Pre-print, not peer-reviewed] The inhaled corticosteroid budesonide reduced time to recovery among older ambulatory SARS-CoV-2-infected adults by 3 days, according to an interim analysis of a randomized, open-label trial (PRINCIPLE Trial). In participants either 65 years and older without co-morbidities or less than 50 years with co-morbidities given 14 days of 800 mcg of budesonide&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/04\/13\/inhaled-budesonide-for-covid-19-in-people-at-higher-risk-of-adverse-outcomes-in-the-community-interim-analyses-from-the-principle-trial\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[28],"topic":[19],"class_list":["post-9108","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-treatment","topic-testing-and-treatment"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9108","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=9108"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9108\/revisions"}],"predecessor-version":[{"id":9109,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9108\/revisions\/9109"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=9108"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=9108"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=9108"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=9108"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}